The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...

Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide). LT3001 is a first-in-class ...

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

Manual review of electronic health records (EHRs) to screen for contraindications to thrombolysis during stroke evaluation is ...

The American Heart Association and American Stroke Association have issued an updated guideline for the diagnosis and treatment of acute ischemic stroke.The new guideline, published in Stroke, ...

As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...

A new scientific statement from the American Heart Association outlines maternal stroke risk and prevention and treatment strategies during pregnancy and postpartum.

Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

Among patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase, a modified human tissue plasminogen activator, administered 4.5 to 24 hours ...

A large US registry-based study shows that longer door-in-door-out (DIDO) times at the referring hospital are strongly ...